MaryL.VanceMD
Endocrinology • Charlottesville, VADiabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Professor of Medicine, University VA School of Medicine
Dr. Vance is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Uva Endocrinology
415 Ray C. Hunt Drive
Charlottesville, VA 22903Phone+1 434-924-1825Fax+1 434-924-9616- Is this information wrong?
Education & Training
University of Virginia Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1980 - 1983
Baylor University Medical CenterResidency, Internal Medicine, 1977 - 1980
Louisiana State University School of Medicine in New OrleansClass of 1977
Certifications & Licensure
VA State Medical License 1981 - 2024
TX State Medical License 1977 - 1993- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Clinical Trials
- Preoperative Bexarotene Treatment for Cushing's Disease Start of enrollment: 2008 Nov 01
Publications & Presentations
PubMed
- Silent Corticotroph Staining Pituitary Neuroendocrine Tumors: Prognostic Significance in Radiosurgery.Georgios A Maragkos, Georgios Mantziaris, Stylianos Pikis, Tomas Chytka, Roman Liscak, Selcuk Peker, Yavuz Samanci, Shray K Bindal, Ajay Niranjan, L Dade Lunsford, Rup...> ;Neurosurgery. 2023 Dec 1
- 1 citationsPostoperative Serum Cortisol and Cushing Disease Recurrence in Patients With Corticotroph Adenomas.Michael P Catalino, Dominic T Moore, Natasha Ironside, Alexander R Munoz, Justin Coley, Rachel Jonas, Kathryn Kearns, Le Min, Mary Lee Vance, John A Jane Jr, Edward R ...> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Nov 17
- 3 citationsEffects of Neuroanatomic Structural Distances on Pituitary Function After Stereotactic Radiosurgery: A Multicenter Study.Ironside, N., Chen, C., Xu, Z., Schlesinger, D., Lee Vance, M., Hong, G., Jane, J., Patel, S., Bindal, S., Niranjan, A., Lunsford, L., Liscak, R., Chytka, T., Jezkova,...> ;Neurosurgery. 2023 May 1
- Join now to see all
Press Mentions
Pathology of Prolactinomas: Any Predictive Value?October 22nd, 2019
Grant Support
- Preoperative Bexarotene Treatment For Cushing'S DiseaseNational Center For Research Resources2010
- Clinical Trial: Effect Of Growth Hormone Treatment On Recovery From Cushing'S DINational Center For Research Resources2008–2010
- Effect Of Growth Hormone Treatment On Recovery From Cushing'S DiseaseNational Center For Research Resources2005–2007
- The Efficacy And Safety;Pegvisomant Vsasandostatin LARNational Center For Research Resources2006
- Pegvisomant;Sandostatin Lar;Pegvisomant PLUS Sandostatin LAR In AcromegalyNational Center For Research Resources2005–2006
- The Efficacy And Safety;Pegvisomant VS Sandostatin LARNational Center For Research Resources2005
- Surgical Debulking;Response To Octreotide LAR, AcromegalyNational Center For Research Resources2005
- Pegvisomant And Sandostatin LAR In AcromegalyNational Center For Research Resources2004
- Efficacy And Safety;Pegvisomant VS Sandostatin LARNational Center For Research Resources2004
- Metabolic Effects Of Growth Hormone In GH Deficient AdulNational Center For Research Resources2000–2002
- B2036-PEG In Treatment Of AcromegalyNational Center For Research Resources2000–2002
- 24 HR Urinary Free Cortisol Excretion In Reponse To Dexamethasone In African AmerNational Center For Research Resources2000–2002
- Sandostatin LARNational Center For Research Resources1999–2002
- Double Blind, Placebo Controlled Trial Of B2036 PEG In AcromegalyNational Center For Research Resources1999–2002
- OPEN Label Trial Of B2036 PEG In Treatment Of AcromegalyNational Center For Research Resources1998–2002
- Lanreotide In AcromegalyNational Center For Research Resources1998–2002
- B2036 PEG In The Treatment Of AcromegalyNational Center For Research Resources1998–1999
- 24-Hr Urinary Free Cortisol Excretion &Dexamethasone Response In WomenNational Center For Research Resources1996–1999
- OPEN Label Pharmokinetic Study Of Prolease Hgh In GH Deficient AdultsNational Center For Research Resources1997
- Oral Dose Regimen Finding Study Of Gpa-748 In GH Deficient AdultsNational Center For Research Resources1996–1997
- Cabergoline In The Treatment Of Prolactin Secreting Pituitary MacroadenomaNational Center For Research Resources1992–1997
- Continuous, Pulsatile, And Single Dose GH Administration In Gh-Deficient AdultsNational Center For Research Resources1995–1996
- Subcutaneous Synthetic Growth Hormone Response Study In Normal ManNational Center For Research Resources1994–1996
- Study Of Nutropin In Treatment Of Growth Hormone Deficient AdultsNational Center For Research Resources1994–1996
- Multicenter Study To Define Safety And Efficacy Of Chronic SandostatinNational Center For Research Resources1995
- Safety Of Chronic Sandostatin Treatment In Acromegalic PatientsNational Center For Research Resources1993–1994
- Sandostatin On GH Secretion And Carbohydrate Lipid And Protein MetabolismNational Center For Research Resources1992
- Dose Ranging Study Of Cgs-15873a In Hypeprolactinemic PatientsNational Center For Research Resources1992
- Subcutaneous Synthetic GH Dose Response Study In Normal ManNational Center For Research Resources1991–1992
- Safety And Efficacy Of Chronic Sandostatin Treatment In Acromegalic PatientsNational Center For Research Resources1990–1992
- Physiologic GH Replacement--Protein, Lipid And Carbohydrate MetabolismNational Center For Research Resources1990–1992
- Growth Hormone Secretion In Burn InjuryNational Center For Research Resources1990–1992
- Efficacy Of CV 205-502 In Patients With HyperprolactinemiaNational Center For Research Resources1989–1992
- GH Suppression--Effect On Proliferative Diabetic RetinopathyNational Center For Research Resources1991
- Sandostatin In The Treatment Of AcromegalyNational Center For Research Resources1990–1991
- Progesterone Therapy On Gonadotropin Secreting Psychological Symptoms In PMSNational Center For Research Resources1990
- Humatrope Effects On Growth Hormone Binding ProteinNational Center For Research Resources1990
- Efficacy, Systemic Tolerance And Topical Safety Of Transdermal TestosteroneNational Center For Research Resources1989–1990
- Diagnosis And Treatment Of Carcinoid Tumors With I-131 MetaiodobenzylguanidineNational Center For Research Resources1989–1990
- Investigation Of CV 201-502 In The Treatment Of Hyperprolactinemic WomenNational Center For Research Resources1987–1990
- Efficacy, Systemic Tolerance, Topical Safety Of Transdermal TestosteroneNational Center For Research Resources1987–1989
- Determination Of The Serum Half Life Of Endogenous GH In Normal MenNational Center For Research Resources1987–1989
- Determination Of Clinical Effects And Dose Response Relationships Of GHNational Center For Research Resources1987–1989
- Progesterone Therapy On Gonadotropin Secreting Psychological SymptomsNational Center For Research Resources1987
- Progesterone Therapy In Premenstrual SyndromeNational Center For Research Resources1986
- Efficacy Of Testosterone Therapy In HypogonadismNational Center For Research Resources1986
- Testolactone Effect On Gonadotropin RegulationEunice Kennedy Shriver National Institute Of Child Health &Human Development1985
Hospital Affiliations
University of Virginia Medical CenterCharlottesville, Virginia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
